Bio-Rad Laboratories anti-biotherapeutic and anti-MMAE antibodies

Wednesday, 10 July, 2024 | Supplied by: Bio-Rad Laboratories Pty Ltd


Bio-Rad Laboratories has launched four anti-idiotypic antibodies to the drugs atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro) and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. It has also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.

The company’s range of ready-made anti-biotherapeutic antibodies enables the development of robust bioanalytical assays against marketed biologic drugs. The anti-idiotypic antibodies are suitable for pharmacokinetic (PK) and antidrug-antibody assays for atezolizumab, avelumab, obinutuzumab and ocrelizumab, enabling therapeutic drug monitoring for innovator and biosimilar products.

The anti-MMAE antibody range supports bioanalysis of antibody-drug conjugates (ADCs) carrying MMAE as payload. MMAE is a potent antimitotic agent that inhibits cell division. Due to its toxicity, MMAE is not used as a drug itself, but instead forms the payload component of ADCs. The anti-MMAE biotherapeutic antibodies enable the development of sensitive assays for both ADCs incorporating the toxin and the toxin itself.

Online: www.bio-rad.com
Phone: 02 9914 2800
Related Products

Enzo Life Sciences SCREEN-WELL Autophagy library

Enzo Life Sciences' SCREEN-WELL Autophagy library contains 94 compounds with defined...

Cytek Biosciences Ghost Dye viability dyes

With Ghost Dye viability dyes, from Cytek Biosciences' Tonbo Reagents portfolio, only live...

List Labs Clostridium difficile toxins

List Labs manufactures highly purified native Clostridium difficile toxins — toxin...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd